IP Library › Granted Patent US 12,280,204
Granted Patent B2
US 12,280,204 · App. 16/073,348 · Granted Apr 22, 2025

Method for measuring flow features in an inhaler, inhaler and system

Inventors: Dominik Ziegler (Basel, CH); Richard Pavkov (East Hanover, NJ)
Assignee: Novartis AG
A61M15/0001A61M15/003A61M15/008A61M16/0003A61M2205/3331A61M2205/3576
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,280,204
App. No.
16/073,348
Granted
Apr 22, 2025
Kind
B2
Abstract

The present invention relates to a method for measuring at least one inhalation flow feature in an inhaler, wherein a capsule containing a formulation is located in the inhaler, the method comprising the steps of sensing an impact feature relating to impacts of the capsule on the inhaler and correlating the impact feature to at least one inhalation flow feature. The present invention also relates to an inhaler adapted to aerosolize a formulation contained in a capsule, wherein the inhaler comprises a sensor for sensing an impact feature relating to impacts of the capsule on the inhaler and a processor for correlating the impact feature to at least one inhalation flow feature. The present invention also relates to a system comprising an inhaler adapted to aerosolize a formulation contained in a capsule and a computing device external of the inhaler, wherein the inhaler comprises a sensor for sensing an impact feature relating to impacts of the capsule on the inhaler and a data-receiving-transmitting means to receive and transmit data from and to the external computing device, wherein the external computing device also comprises data-receiving-transmitting means to receive and transmit data from and to the inhaler, wherein the inhaler and/or the external computing device comprises processing means for correlating the impact feature to at least one inhalation flow feature.

Claims (30)

1. A method for measuring at least one inhalation flow feature in an inhaler, wherein a capsule containing a formulation is located in the inhaler, the method comprising:

sensing an impact feature relating to impacts of the capsule on the inhaler during a single inhalation,

dividing the sensed impact feature into time intervals within the single inhalation,

determining a mean value of the sensed impact feature for the time intervals,

correlating the mean value of the sensed impact feature to an inhalation flow volume for each of the time intervals, determining a peak-to-mean ratio of the sensed impact feature for the time intervals, and correlating the peak-to-mean ratio of the sensed impact feature to an inhalation flow volume.

2. The method according to claim 1 , wherein the impact feature is a sound generated by the impacts of the capsule on the inhaler.

3. The method according to claim 1 , wherein the sensing the impact feature and the correlating the mean value of the sensed impact feature are performed for a plurality of inhalations.

4. The method according to claim 1 , further comprising combining the inhalation flow volumes for each of the time intervals to determine an overall inhalation flow volume.

5. The method according to claim 4 , wherein combining the inhalation flow volumes for each of the time intervals includes averaging the inhalation flow volumes for each of the time intervals.

6. The method according to claim 4 , wherein combining the inhalation flow volumes for each of the time intervals includes providing different weights to the inhalation flow volumes for each of the time intervals.

7. The method according to claim 1 , wherein each of the time intervals has a predetermined duration.

8. The method according to claim 1 , wherein correlating the mean value of the sensed impact feature to the inhalation flow volume for each of the time intervals is performed after confirming, via a processor, that the capsule is located in the inhaler.

9. The method according to claim 1 , wherein sensing the impact feature is performed continuously during multiple inhalations.

10. An inhaler adapted to aerosolize a formulation contained in a capsule, wherein the inhaler comprises:

a sensor adapted to sense an impact feature relating to impacts of the capsule on the inhaler during a single inhalation, and

a processor adapted to divide the sensed impact feature into time intervals within the single inhalation, wherein the processor is adapted to determine a mean value of the impact feature for the time intervals, wherein the processor is adapted to correlate the mean value of the impact feature to an inhalation flow volume for each of the time intervals, wherein the processor is adapted to determine a peak-to-mean ratio of the impact feature for the time intervals, and wherein the processor is adapted to correlate the peak-to-mean ratio of the impact feature to an inhalation flow volume.

11. The inhaler according to claim 10 , wherein the sensor is a microphone.

12. The inhaler according to claim 10 , wherein the inhaler comprises a data-receiving-transmitting means to receive and transmit data from and to an external device.

13. A system comprising an inhaler according to claim 10 and an external computing device external to the inhaler, wherein the inhaler comprises a data-receiving-transmitting means to receive and transmit data from and to the external computing device, wherein the external computing device also comprises data-receiving-transmitting means to receive and transmit data from and to the inhaler.

14. A method for measuring at least one inhalation flow feature in an inhaler, wherein a capsule containing a formulation is located in the inhaler, the method comprising:

sensing an impact feature relating to impacts of the capsule on the inhaler,

determining over an interval of time a mean value of the impact feature, and

correlating the mean value of the impact feature to an inhalation flow volume over the interval of time,

determining over the interval of time a peak-to-mean ratio of the impact feature, and

correlating the peak-to-mean value of the impact feature to an inhalation flow volume.

15. The method according to claim 14 , wherein the inhalation flow volume correlated from the mean value of the impact feature and the flow volume correlated from the peak-to-mean ratio are averaged.

16. An inhaler adapted to aerosolize a formulation contained in a capsule, wherein the inhaler comprises:

a sensor adapted to sense an impact feature relating to impacts of the capsule on the inhaler, and

a processor adapted to determine over an interval of time a mean value of the impact feature and wherein the processor is adapted to correlate the mean value of the impact feature to an inhalation flow volume over the interval of time, wherein the processor is further adapted to determine over the interval of time a peak-to-mean ratio of the impact feature and to correlate the peak-to-mean value of the impact feature to an inhalation flow volume.

17. The inhaler according to claim 16 , wherein the processor is adapted to average the inhalation flow volume correlated from the mean value of the impact feature and the flow volume correlated from the peak-to-mean ratio.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: PAVKOV, RICHARD
To: NOVATIS PHARMACEUTICALS COPORATION
Reel/Frame 047028/0532 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: NOVATIS PHARMACEUTICALS COPORATION
To: NOVARTIS AG
Reel/Frame 047028/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: ZIEGLER, DOMINIK
To: NOVARTIS PHARMA AG
Reel/Frame 047028/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 047028/0623 →
Priority Claims (1)
EP 16153186 · Jan 28, 2016 · regional
Continuity (1)
Related Publication 20190030262A1 · Jan 31, 2019
References Cited (81)
US 6178302B1 · Nagashima · 2001 [cited by applicant]
US 6958691B1 · Anderson · 2005 [cited by applicant]
US 7151456B2 · Godfrey · 2006 [cited by applicant]
US 7191777B2 · Brand · 2007 [cited by applicant]
US 7721730B2 · Hamano · 2010 [cited by applicant]
US 8251914B2 · Daniels · 2012 [cited by examiner]
US 8424517B2 · Sutherland · 2013 [cited by examiner]
US 8474452B2 · Matter · 2013 [cited by applicant]
US 8479730B2 · Ziegler · 2013 [cited by applicant]
US 8622241B2 · Geboers · 2014 [cited by applicant]
US 8807131B1 · Tunnell · 2014 [cited by applicant]
US 9016147B2 · Adamo · 2015 [cited by applicant]
US 9242056B2 · Andersen · 2016 [cited by applicant]
US 9390457B2 · Baym · 2016 [cited by applicant]
US 9555200B2 · Hosemann · 2017 [cited by examiner]
US 9744319B2 · Denyer · 2017 [cited by applicant]
US 10029056B2 · Anderson · 2018 [cited by applicant]
US 10463816B2 · Calderon Oliveras · 2019 [cited by examiner]
US 20020189615A1 · Henry · 2002 [cited by applicant]
US 20030074223A1 · Hickle · 2003 [cited by applicant]
US 20040025877A1 · Crowder · 2004 [cited by applicant]
US 20050087473A1 · Fabricius · 2005 [cited by applicant]
US 20080110452A1 · Kotnik · 2008 [cited by applicant]
US 20090308387A1 · Andersen · 2009 [cited by examiner]
US 20100097380A1 · Daniels · 2010 [cited by examiner]
US 20110298587A1 · Walz · 2011 [cited by applicant]
US 20120003928A1 · Tsvey · 2012 [cited by applicant]
US 20120247235A1 · Adamo · 2012 [cited by applicant]
US 20130146613A1 · Balthes · 2013 [cited by applicant]
US 20130151162A1 · Harris · 2013 [cited by applicant]
US 20140000603A1 · Hosemann · 2014 [cited by examiner]
US 20140106324A1 · Adams · 2014 [cited by applicant]
US 20140182854A1 · Mukhopadhyay · 2014 [cited by applicant]
US 20150174349A1 · Tunnell · 2015 [cited by applicant]
US 20150196724A1 · Adamo · 2015 [cited by examiner]
US 20150196728A1 · Aldana · 2015 [cited by applicant]
US 20160081651A1 · Nam · 2016 [cited by examiner]
US 20160256639A1 · Sickle · 2016 [cited by applicant]
EP 2686049B1 · 2015 [cited by applicant]
EP 2859906 · 2015 [cited by applicant]
EP 3199193A1 · 2017 [cited by applicant]
EP 3407945B1 · 2022 [cited by applicant]
JP 2006153760A · 2006 [cited by applicant]
JP 2010160230A2 · 2010 [cited by applicant]
JP A2011174788 · 2011 [cited by applicant]
RU 2372105C2 · 2009 [cited by applicant]
WO WO1992017231 · 1992 [cited by applicant]
WO WO2003020349 · 2002 [cited by applicant]
WO WO2005113042 · 2005 [cited by applicant]
WO WO2007101438 · 2007 [cited by applicant]
WO WO2010066456 · 2010 [cited by applicant]
WO WO2011056889 · 2011 [cited by applicant]
WO WO2011130583 · 2011 [cited by applicant]
WO WO2012123448 · 2012 [cited by applicant]
WO 2013016784A1 · 2013 [cited by applicant]
WO WO2014033229 · 2014 [cited by applicant]
WO WO2014204511 · 2014 [cited by applicant]
WO 2015127258 · 2015 [cited by applicant]
Holmes, “A Method of Estimating Inspiratory Flow Rate and Volume from an Inhaler Using Acoustic Measurements” [cited by applicant]
Coates, “Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses” Pharm Res. 22(9):1445-53, Sep. 2005. [cited by applicant]
Coates, “The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses” 22(6):923-932 Jun. 2005. [cited by applicant]
BR Examination Report—May 12, 2020—No. BR112017028579-7. [cited by applicant]
CNIPA examination report Mar. 9, 2020 No. 201680046268.6. [cited by applicant]
EPO Examination Report—Apr. 3, 2020—No. 15175216.9. [cited by applicant]
EPO Examination Report—Aug. 7, 2018—No. 15175216.9. [cited by applicant]
EPO Examination Report—Jul. 20, 2020—No. 16741882.1. [cited by applicant]
EPO Search Report—Sep. 24, 2015—No. 15 175216.9. [cited by applicant]
JP Office Action Mar. 3, 2019—No. 2017-567301 (English translation). [cited by applicant]
Official Action—Jan. 31, 2019 RU No. 2018103754/14. [cited by applicant]
Search Report—Jan. 29, 2019 RU No. 2018103754/14. [cited by applicant]
Search Report and Written Opinion PCT/EP2016/051389. [cited by applicant]
US PTO Notice of References Cited for U.S. Appl. No. 15/545,375, dated Oct. 14, 2020. [cited by applicant]
Flume, PA et al. “Optimising inhaled mannitol for cystic fibrosis in an adult population.” Breathe (Sheff). Mar. 2015, 11(1), pp. 39-48. [cited by applicant]
Supplemental video “Inhalation technique” downloadable from “https://breathe.ersjournals.com/content/11/1/13.figures-only” Date of publication unknown, link and screenshots provided. [cited by applicant]
Rau, Joseph L., “Practical Problems With Aerosol Therapy in COPD” Special Articles, Respiratory Care, Feb. 2006, vol. 51, No. 2, pp. 158-172. [cited by applicant]
Rx Files, “COPD New Drugs, New Devices and Considerations for Best Practice” Sep. 2015, author unknown. [cited by applicant]
Notice of Opposition to European Patent EP3407945, Application No./Patent No. 17704675.2-1122/3407945, by Kilburn & Strode LLP, filed Feb. 10, 2023. [cited by applicant]
Statement of Ground for Appeal for Eurpean Patent No. EP3199193 by Kilburn & Strode LLP, filed Apr. 21, 2023. [cited by applicant]
U.S. Appl. No. 15/741,630. [cited by applicant]
U.S. Appl. No. 17/499,488. [cited by applicant]
U.S. Appl. No. 15/545,375. [cited by applicant]